Search hospitals > Alaska > Anchorage
Alaska Oncology and Hematology LLC
Claim this profileAnchorage, Alaska 99508
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Cancer
Conducts research for Breast cancer
210 reported clinical trials
8 medical researchers
Summary
Alaska Oncology and Hematology LLC is a medical facility located in Anchorage, Alaska. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Breast cancer and other specialties. Alaska Oncology and Hematology LLC is involved with conducting 210 clinical trials across 403 conditions. There are 8 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Krishna C. Alluri.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage II
Stage III
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Alison K. ConlinProvidence Portland Medical Center6 years of reported clinical research
Expert in Breast Cancer
Expert in Cancer
107 reported clinical trials
183 drugs studied
Charles W. DrescherProvidence Portland Medical Center8 years of reported clinical research
Studies Breast Cancer
Studies Non-Small Cell Lung Cancer
53 reported clinical trials
99 drugs studied
Nitya AlluriProvidence Portland Medical Center2 years of reported clinical research
Studies Uterine Cancer
Studies Endometrial Adenocarcinoma
28 reported clinical trials
79 drugs studied
Krishna C. AlluriProvidence Portland Medical Center5 years of reported clinical research
Studies Ovarian Carcinoma
Studies Ovarian Cancer
26 reported clinical trials
63 drugs studied
Clinical Trials running at Alaska Oncology and Hematology LLC
Lung Cancer
Bladder Cancer
Pancreatic Cancer
Prostate Cancer
Breast Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer
Esophageal cancer
Multiple Myeloma
Bladder Carcinoma
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Alaska Oncology and Hematology LLC?
Alaska Oncology and Hematology LLC is a medical facility located in Anchorage, Alaska. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Breast cancer and other specialties. Alaska Oncology and Hematology LLC is involved with conducting 210 clinical trials across 403 conditions. There are 8 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Krishna C. Alluri.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.